Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder
Authors:
- Jean-Pierre LindenmayerJLJean-Pierre Lindenmayer
- Akbar KhanAKAkbar Khan
- Mariëlle EerdekensMEMariëlle Eerdekens
- Ilse Van HoveIHIlse Van Hove
- Stuart KushnerSKStuart Kushner
- 1 January 2007
- journal article
- research article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 17 (2) , 138-144
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophreniaSchizophrenia Research, 2005
- Comparative efficacy and safety of long-acting risperidone and risperidone oral tabletsEuropean Neuropsychopharmacology, 2005
- Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorderJournal of Affective Disorders, 2004
- Efficacy and safety of long‐acting risperidone in elderly patients with schizophrenia and schizoaffective disorderInternational Journal of Geriatric Psychiatry, 2004
- Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidoneEuropean Psychiatry, 2004
- Treatment of Schizophrenia With Long-Acting Injectable RisperidoneThe Journal of Clinical Psychiatry, 2003
- Treatment of schizophrenia: preventing the progression of diseasePsychiatric Clinics of North America, 2003
- Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical AntipsychoticAmerican Journal of Psychiatry, 2003
- Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical AntipsychoticsAmerican Journal of Psychiatry, 2003
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987